RT Journal Article
SR Electronic
T1 Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 600
OP 609
DO 10.3899/jrheum.110947
VO 39
IS 3
A1 DIMITRIOS KARRAS
A1 IVAYLO STOYKOV
A1 WILLEM F. LEMS
A1 BENTE L. LANGDAHL
A1 ÖSTEN LJUNGGREN
A1 ANNABEL BARRETT
A1 J. BERNARD WALSH
A1 ASTRID FAHRLEITNER-PAMMER
A1 GERALD RAJZBAUM
A1 FRANZ JAKOB
A1 FERNANDO MARIN
YR 2012
UL http://www.jrheum.org/content/39/3/600.abstract
AB Objective. To describe clinical fracture rates, back pain, and health-related quality of life (HRQOL) in postmenopausal women with osteoporosis who are receiving glucocorticoids (GC), during a 36-month study of teriparatide treatment for up to 18 months, with an additional 18-month followup period when patients were receiving other osteoporosis medications. Methods. A prospective, multinational, observational study. Data for clinical fractures, back pain (by visual analog scale; VAS) and HRQOL (by EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month segments and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed. Results. Of 1581 enrolled women with followup data, 294 (18.6%) had antecedents of GC use. Of these, 49 (16.7%) patients sustained a total of 69 fractures during the 36-month study period. Adjusted odds of fracture were significantly decreased during the last year of followup compared with the first 6 months of teriparatide treatment: an 81% decrease in the 24 to < 30-month period (p < 0.05), and an 89% decrease in the 30 to < 36-month period (p < 0.05). There were significant reductions in back pain and improvements in HRQOL in both groups of GC users and nonusers. Conclusion. Postmenopausal women with severe osteoporosis receiving GC, who were treated with teriparatide for up to 18 months, showed a reduced incidence of clinical fractures during the third year while receiving sequential osteoporosis treatments compared with the first 6 months, together with reduced back pain and improved HRQOL. Our results should be interpreted in the context of an uncontrolled observational study in a routine clinical setting.